Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026

Editas Medicine, Inc.

Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.
Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.
Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.
Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.
First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.